WCLC - Daily Conference Newsletter

Saturday 1 August (PDF)
Sunday 2 August (PDF)
Monday 3 August (PDF)
Tuesday 4 August (PDF)

Press Programme

#1 Press Conference - Targeted Therapies

Download Presentation Slides for Press Conference (PDF)

Saturday 1 August - 10:00 - 11:00, Moscone West, Room 2012, Level 2
Moderator: David Gandara (UC Davis Cancer Center, USA)

B9.5*: Clinical outcomes of patients with epidermal growth factor receptor (EGFR) mutations (mut) in IPASS (IRESSATM Pan Asia Study) - Tony Mok (The Chinese University of Hong Kong, China)
A2.1: Efficacy and safety of erlotinib as first-line maintenance in NSCLC following nonprogression with chemotherapy: results from the phase III SATURN study - Federico Cappuzzo (Istituto Clinico Humanitas IRCCS, Italy)
B9.1: Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC - Wolfram Brugger (Schwarzwald-Baar Clinic, Germany)
C2.2*: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced NSCLC: a randomized, double-blind phase III trial (ZODIAC) - Roy Herbst (MD Anderson Cancer Center, USA)
C6.1: Efficacy of maintenance erlotinib versus placebo in patients with unresectable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiation (D0410, NCT00153803) - James Rigas (Dartmouth Medical School, USA)

* This research, while presented prior to the IASLC World Conference, are included to provide context to the current state of science in the target therapies arena.

#2 Press Conference - Early Detection and Prevention
Sunday 2 August - 10:00 - 11:00, Moscone West, Room 2012, Level 2
Moderator: Paul A. Bunn, Jr. (University of Colorado Denver, USA)

Download Presentation Slides for Press Conference - REVISED (PDF)

B3.5: The unique “smell print” of NSCLC cell lines - Nir Peled (University of Colorado Cancer Center; University of Colorado Denver, USA)
D1.6: Oral iloprost improves endobronchial dysplasia in former smokers - Robert Keith (Denver VAMC/UC Denver, USA)
D1.3: The lung cell evaluation device (LuCED): early detection of lung cancer in sputum based on 3D morphology - Michael Meyer (VisionGate, USA)
D1.5: Methylation analysis in spontaneous sputum is suitable for lung cancer diagnosis - Erik Thunnissen (Pathology, Vumc, Netherlands)

#3 Press Conference - Multi-Modality Treatments
Monday 3 August - 10:00 - 11:00, Moscone West, Room 2012, Level 2
Moderator: Peter Goldstraw (Royal Brompton Hospital, UK)

Download Presentation Slides for Press Conference - REVISED (PDF)

PRS.3: A phase III randomized trial of surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cancer (NSCLC): NATCH follow-up data - Enriqueta Felip (Vall d'Hebron University Hospital, Spain)
C6.6: A phase III comparison of prophylactic cranial irradiation (PCI) versus observation in patients with locally advanced non-small cell lung cancer (LA-NSCLC). Initial analysis of primary and secondary endpoints: RTOG 0214. - Alex Sun (Princess Margaret Hospital, Canada)
PRS.4: A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung - Jin Soo Lee (National Cancer Center Korea, South Korea)

Media and Embargo Policy

Download the official Media and Embargo Policy for WCLC 2009

Stay tuned for official IASLC press conference information, including scheduled Press Conferences taking place during WCLC 2009. Press materials and teleconferences will be available to U.S. and international media.

For More Information:
Liz Wulderk
Spectrum Science Communications
+1 202 587 2526
lwulderk@spectrumscience.com

Mary Ellen Hackett
Spectrum Science Communications
+1 202 587 2511
mehackett@spectrumscience.com

Press & Media Registration

Please contact Spectrum Science Communications to recieve information regarding Press & Media registration & hotel accommodations for the 13th World Conference on Lung Cancer.

Founded in 1972, the International Association for the Study of Lung Cancer (IASLC) is an international organization of 2,000 lung cancer specialists, spanning 53 countries. IASLC members work towards developing and promoting the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer. IASLC’s mission is to enhance the understanding and education of lung cancer to scientists, members of the medical community and the public. In addition to the biannual meeting, the IASLC publishes the Journal of Thoracic Oncology, a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.